Matrix metalloproteinases in digestive pathology;Metalloproteases matricielles en pathologie digestive

Gastroenterologie Clinique et Biologique

Volumn 23, Issue 3, 1999, Pages 330-341

  Aparicio, Thomas ^a   Lehy, Thérèse ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Angiogenesis; Digestive cancer; Extracellular matrix; Hepatic fibrosis; Inflammatory bowel disease; Therapy; Tumoral invasion

Indexed keywords

CELL ADHESION MOLECULE; COLLAGENASE; CYTOKINE; GLUCOCORTICOID; GROWTH FACTOR; MATRIX METALLOPROTEINASE; PROSTAGLANDIN; RETINOIC ACID; STROMELYSIN; METALLOPROTEINASE;

CANCER INVASION; DIGESTIVE SYSTEM CANCER; ENTERITIS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; LIVER FIBROSIS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; CHEMISTRY; DIGESTIVE SYSTEM DISEASE; DIGESTIVE SYSTEM TUMOR; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; PHYSIOLOGY;

DIGESTIVE SYSTEM DISEASES; DIGESTIVE SYSTEM NEOPLASMS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; METALLOENDOPEPTIDASES;

EID: 0033086960     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Pendas AM, Knauper V, Puente XS, Llano E, Mattei MG, Apte S, et al. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem 1997;272: 4281-6.
2. Bartlett JD, Simmer JP, Xue J, Margolis HC, Moreno EC. Molecular cloning and mRNA tissue distribution of a novel matrix metalloproteinase isolated from porcine enamel organ. Gene 1996;183:123-8.
3. Llano E, Pendas AM, Knauper V, Sorsa T, Salo T, Salido E, et al. Identification and structural and functional characterization of human enamelysin (MMP-20). Biochemistry 1997;36:15101-8.
4. Brooks PC, Strömblad S, Sanderds LC, Von Schalscha TL, Aimes RT, Stettler-Stevenson WG, et al. Localization of matrix metallo-proteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 1996;85:683-93.
5. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997;378:151-60.
6. Imai K, Ohuchi E, Aoki T, Nomura H, Fuii Y, Sato H, et al. Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2. Cancer Res 1996;56:2707-10.
7. Baramova EN, Bajou K, Remade A, L'Hoir C, Krell HW, Weidle UH, et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 1997;405:157-62.
8. Lee AY, Akers KT, Collier M, Li L, Eisen AZ, Seltzer JL. Intracellular activation of gelatinase A (72-kDa type IV collagenase) by normal fibroblasts. Proc Natl Acad Sci USA 1997;94: 4424-9.
9. Theret N, Musso O, L'Helgoualc'h A, Clement B. Activation of matrix metalloproteinase-2 from hepatic stellate cells requires interactions with hepatocytes. Am J Pathol 1997;150:51-8.
10. Giambernardi TA, Grant GM, Taylor GP, Hay RJ, Maher VM, McCormick JJ, et al. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol 1998;16:483-96.
11. Yoshida K, Tsujino T, Yasui W, Kameda T, Sano T, Nakayama H, et al. Induction of growth factor-receptor and metalloproteinase genes by epidermal growth factor and/or transforming growth factor-α in human gastric carcinoma cell line MKN-28. Jpn J Cancer Res 1990;81:793-8.
12. Kermorgant S, Aparicio T, Lewin MJM, Lehy T. Hepatocyte Growth Factor (HGF), c-Met, métalloprotéinases matricielles (MMPs) et différenciation cellulaire de la lignée cancéreuse colique Caco-2 (abstract). Gastroenterol Clin Biol 1998;22:200
13. Aparicio T, Kermorgant S, Lewin MJM, Lehy T. Effets de l'HGF sur la production de métalloprotéinases matricielles par les cellules cancéreuses coliques DHD/K12. C R Soc Biol (Paris) 1998;192:311-5.
14. Uchiyama A, Essner R, Doi F, Nguyen T, Ramming KP, Nakamura T, et al. Interleukin 4 inhibits hepatocyte growth factor-induced invasion and migration of colon carcinomas. J Cell Biochem 1996;62:443-53.
15. Arima N, Shima I, Shimajiri S, Sasaguri Y, Sasaguri T, Tanimoto A, et al. Phenotypes of human esophageal squamous cell carcinoma based on matrix metalloproteinase production. Int J Oncol 1997;10:269-77.
16. Koshiba T, Hosotani R, Wada M, Miyamoto Y, Lee JU, Fujimoto K, et al. TGFß1 activates matrix metalloproteinase-2 in PANC-1 cells (abstract). Gastroenterology 1997;112 : A594.
17. Hyuga S, Nishikawa Y, Sakata K, Tanaka H, Yamagata S, Sugita K, et al. Autocrine factor enhancing the secretion of M(r) 95,000 gelatinase (matrix metalloproteinase 9) in serum-free medium conditioned with murine metastatic colon carcinoma cells. Cancer Res 1994;54:3611-6.
18. Shimizu S, Nishikawa Y, Kudora K, Takagi S, Kozaki KI, Huyga S, et al. Involvement of transforming growth factor βi1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells. Cancer Res 1996;56:3366-70.
19. Arribas J, Coodly L, Vollmer P, Kishimoto TK, Rose-John S, Massagué J. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem 1996;271:11376-82.
20. Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem 1997;272:31730-7.
21. Watanabe N, Nakada K, Kobayashi Y. Processing and release of tumor necrosis factor alpha. Eur J Biochem 1998;253:576-82.
22. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994;370:555-7.
23. McGeehan GM, Becherer JD, Bast RC, Jr., Boyer CM, Champion B, Connolly KM, et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 1994;370:558-61.
24. Saren P, Welgus HG, Kovanen PT. TNF-alpha and IL-1 beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 1996;157:4159-65.
25. Pender SLF, Breese EJ, Gunther U, Howie D, Wathen NC, Schuppan D, et al. Suppression of T cell-mediated injury in human gut by interleukin 10 : role of matrix metalloproteinases. Gastroenterology 1998;115:573-83.
26. Benbow U, Brinckerhoff CE. The AP-1 site and MMP gene regulation : What is all the fuss about ? Matrix Biology 1997;15:519-26.
27. Von Marschall Z, Riecken EO, Rosewicz S. Stromelysin 3 is overexpressed in human pancreatic carcinoma and regulated by retinoic acid in pancreatic carcinoma cell lines. Gut 1998;43: 692-8.
28. Zeng L, An SZ, Goetzl EJ. Regulation of expression of matrix metalloproteinase-9 in early human T cells of the HSB.2 cultured line by the EP (3) subtype of prostaglandin E (2) receptor. J Biol Chem 1996;271:27744-50.
29. Segain JP, Harb J, Gregoire M, Meflah K, Menanteau J. Induction of fibroblast gelatinase B expression by direct contact with cell lines derived from primary tumor but not from metastases. Cancer Res 1996;56:5506-12.
30. Kataoka H, Meng JY, Uchino H, Nabeshima K, Kihira Y, Matuo Y, et al. Modulation of matrix metalloproteinase-7 (matrilysin) secretion in coculture of human colon carcinoma cells with fibroblasts from orthotopic and ectopic organs. Oncol Res 1997;9:101-9.
31. Borchers AH, Sanders LA, Bowden GT. Regulation of matrilysin expression in cells of squamous cell carcinoma by E-cadherin mediated cell-cell contact. J Cancer Res Clin Oncol 1997;123:13-20.
32. Arii S, Mise M, Harada M, Furutani M, Ishigami S, Niwano M, et al. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 1996;24:316-22.
33. Honda M, Mori M, Ueo H, Sugimachi K, Akiyoshi T. Matrix metalloproteinase-7 expression in gastric carcinoma. Gut 1996;39: 444-8.
34. Levy AT, Coice V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA, et al. Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 1991;51:439-44.
35. Nakatsukasa H, Ashida K, Ohguchi S, Tsuboi S, Hino N, Nouso K, et al. Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinoma. Hepatology 1996;24:82-8.
36. Newell KJ, Witty JP, Rodgers WH, Matrisian LM. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinogen 1994;10:199-206.
37. Zeng ZS, Guillem JG. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases. Br J Cancer 1995;72:575-82.
38. Parsons SL, Watson SA, Brown PD, Collins HM, Steele RJC. Matrix metalloproteinases. Br J Surg 1997;84:160-6.
39. Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P, et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 1995;92: 2730-4.
40. Watanabe M, Takahashi Y, Ohta T, Mai M, Sasaki T, Seiki M. Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase 1 gene in nude mice. Cancer 1996;77:1676-80.
41. Watson SA, Morris TM, Parsons SL, Steele RJC, Brown PD. Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Br J Cancer 1996;74:1354-8.
42. Witty JP, McDonnell S, Newell KJ, Cannon P, Navre M, Tressler RJ, et al. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res 1994;54:4805-12.
43. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2:461-2.
44. Ohtani H, Motohashi H, Sato H, Seiki M, Nagura H. Dual over-expression pattern of membrane-type metalloproteinase-1 in cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoelectron microscopy. Int J Cancer 1996;68:565-70.
45. Hewitt RE, Leach IH, Powe DG, Clark IM, Cawston T, Turner DR. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer 1991;49: 666-72.
46. Theret N, Musso O, Campion JP, Turlin B, Loreal O, L'Helgoualc'h A, et al. Overexpression of matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 in liver from patients with gastrointestinal adenocarcinoma and no detectable metastasis. Int J Cancer 1997;74:426-32.
47. Parsons SL, Collins HM, Clarke PA, Watson SA, Steele RJC. Expression of matrix metalloproteinases in colorectal adenomas and carcinomas (abstract). Gastroenterology 1997;112 : A636.
48. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 1996;56:190-6.
49. Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996;14:3133-40.
50. Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P, et al. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer 1995;64:70-5.
51. Ichikawa Y, Ishikawa T, Momiyama N, Yamaguchi S, Masui H, Hasegawa S, et al. Detection of regional lymph node metastases in colon cancer by RT-PCR for matrix metalloproteinase 7, matrilysin. Clin Exp Metast 1998;16:3-8.
52. Ishikawa T, Ichikawa Y, Mitsuhashi M, Momiyama N, Chishima T, Tanaka K, et al. Matrilysin is associated with progression of colorectal tumor. Cancer Lett 1996;107:5-10.
53. Momiyama N, Koshikawa N, Ishikawa T, Ichikawa Y, Hasegawa S, Nagashima Y, et al. Inhibitory effect of matrilysin antisense oligonucleotides on human colon cancer cell invasion in vitro. Mol Carcinogen 1998;22:57-63.
54. Takeuchi N, Ichikawa Y, Ishikawa T, Momiyama N, Hasegawa S, Nagashima Y, et al. Matrilysin gene expression in sporadic and familial colorectal adenomas. Mol Carcinogen 1997;19:225-9.
55. Wilson CL, Heppner KJ, Labosky PA, Hogan BLM, Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 1997;94: 1402-7.
56. Zeng ZS, Cohen AM, Zhang ZF, Stettler-Stevenson W, Guillem JG. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1995;1:899-906.
57. Ring P, Johansson K, Hoyhtya M, Rubin K, Lindmark G. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer - a predictor of tumour stage. Br J Cancer 1997;76:805-11.
58. Yamashita K, Azumano I, Mai M, Okada Y. Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas, implications for vessel invasion and metastasis. Int J Cancer 1998;79:187-94.
59. Senota A, Itoh F, Yamamoto H, Adachi Y, Hinoda Y, Imai K. Relation of matrilysin messenger RNA expression with invasive activity in human gastric cancer. Clin Exp Metast 1998;16:313-21.
60. Sakurai Y, Otani Y, Kameyama K, Hosoda Y, Okazaki I, Kubota T, et al. Expression of interstitial collagenase (matrix metalloproteinase-1) in gastric cancers. Jpn J Cancer Res 1997;88:401-6.
61. Inoue T, Chung YS, Yashiro M, Nishimura S, Maeda K, Sawada T, et al. The expression of matrix metalloproteinase-1 of gastric cancer cells is associated with peritoneal dissemination (abstract). Proc Am Assoc Cancer Res 1997;38:409.
62. Allgayer H, Babic R, Beyer BCM, Grützner KU, Tarabichi A, Schildberg FW, et al. Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer. Oncology 1998;55:152-60.
63. Sier CFM, Kubben FJGM, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996;74:413-7.
64. Endo K, Maehara Y, Baba H, Yamamoto M, Tomisaki S, Watanabe A, et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res 1997;17:2253-8.
65. Mori M, Mimori K, Shiraishi T, Fujie T, Baba K, Kusumoto H, et al. Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int J Cancer 1997;74:316-21.
66. Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 1997;76:531-6.
67. Porte H, Triboulet JP, Kotelevets L, Carrat F, Prévot S, Nordlinger B, et al. Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma : implications for prognosis. Clin Cancer Res 1998;4:1375-82.
68. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185:256-61.
69. Bramhall SR, Neoptolemos JP, Stamp GWH, Lemoine NR. Imbalance of expression of matrix metalloproteinases (MMPS) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997;182:347-55.
70. Koshiba T, Hosotani R, Wada M, Miyamoto Y, Fujimoto K, Lee JU, et al. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998;82: 642-50.
71. Imamura T, Ohshio G, Mise M, Harada T, Suwa H, Okada N, et al. Expression of membrane-type matrix metalloproteinase-1 in human pancreatic adenocarcinomas. J Cancer Res Clin Oncol 1998;124:65-72.
72. Tomita T, Iwata K. Gelatinases and inhibitors of gelatinases in pancreatic islets and islet cell tumors. Modern Pathol 1997;10:47-54.
73. Okazaki I, Wada N, Nakano M, Saito A, Takasaki K, Doi M, et al. Difference in gene expression for matrix metalloproteinase-1 between early and advanced hepatocellular carcinomas. Hepatology 1997;25:580-4.
74. Yamamoto H, Itoh F, Adachi Y, Sakamoto H, Adachi M, Hinoda Y, et al. Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma. Gastroenterology 1997;112:1290-6.
75. Harada T, Arii S, Mise M, Imamura T, Higashitsuji H, Furutani M, et al. Membrane-type matrix metalloproteinase-1(MT1-MMP) gene is overexpressed in highly invasive hepatocellular carcinomas. J Hepatol 1998;28:231-9.
76. Musso O, Theret N, Campion JP, Turlin B, Milani S, Grappone C, et al. In situ detection of matrix metalloproteinase-2 (MMP2) and the metalloproteinase inhibitor TIMP2 transcripts in human primary hepatocellular carcinoma and in liver metastasis. J Hepatol 1997;26:593-605.
77. Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nambu S, et al. Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology 1997;26:1521-9.
78. Ebata M, Fukuda Y, Nakano I, Katano Y, Fujimoto N, Hayakawa T. Serum levels of tissue inhibitor of metalloproteinases-2 and of precursor form of matrix metalloproteinase-2 in patients with liver disease. Liver 1997;17:293-9.
79. Murawaki Y, Ikuta Y, Idobe Y, Kitamura Y, Kawasaki H. Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J Hepatol 1997;26:1213-9.
80. Kasahara A, Hayashi N, Mochizuki K, Oshita M, Katayama K, Kato M, et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C - Relationship to Interferon response. J Hepatol 1997;26:574-83.
81. George DK, Ramm GA, Powell LW, Fletcher LM, Walker NI, Cowley LL, et al. Evidence for altered hepatic matrix degradation in genetic haemochromatosis. Gut 1998;42:715-20.
82. Otani Y, Igarashi N, Yokoyama T, Ishikawa H, Sakurai Y, Kameyama K, et al. Role of matrix metalloproteinases in gastric ulcer formation (abstract). Gastroenterology 1997;112:A248.
83. Ohmiya N, Saga S, Ohbayashi M, Kozaki K, Miyaishi O, Kobayashi M, et al. Kinetics and collagenolytic role of eosinophils in chronic gastric ulcer in the rat. Histochem Cell Biol 1997;108:27-34.
84. Ohtsuka H, Mizukami Y, Onji M. Relationship between tissue inhibitor of metalloproteinase-1 (TIMP-1) and gastric ulcer healing (abstract). Gastroenterology 1997;112:A242.
85. Windle HJP, Kelleher D. Identification and characterization of a metalloprotease activity from Helicobacter pylori. Infect Immun 1997;65:3132-7.
86. Ochi K, Matsumura N, Yamamoto R, Chowdhury R, Muzushima T, Tanaka J, et al. Prolyl hydroxylase and tissue inhibitor of metalloproteinase in pure pancreatic juice in patients with chronic pancreatitis. Pancreas 1998;16:487-90.
87. Schöpper H, Matthes H, Riecken EO, Schuppan D. Differentiation of inflammatory bowel diseases by quantitation of interstitial collagenase (MMP-1) from intestinal biopsies (abstract). Gastroenterology 1997;112 : A401.
88. Baert F, Geboes K, Paemen L, Opdenakker G, D'Haens G, Peeters M, et al. Expression of gelatinase B in early recurrent Crohn's disease (abstract). Gastroenterology 1997;112 : A926.
89. Bailey CJ, Hembry RM, Alexander A, Irving MH, Grant ME, Shuttleworth CA. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol 1994;47:113-6.
90. Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, Kere J, Saarialho-Kere U. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 1998;152:1005-14.
91. Günther U, Herbst H, Matthes H, Stallmach A, Riecken EO, Schuppan D. Deranged pattern of collagen synthesis and degradation in collagenous colitis (abstract). Gastroenterology 1997;112 : A365.
92. Daum S, Bauer U, Foss HD, Schuppan D, Stein H, Riecken EO, et al. Cellular expression of MMP-1 and collagen 1 mRNA in celiac disease (abstract). Gastroenterology 1997;112 : A357.
93. Pender SLF, Tickle SP, Docherty AJP, Howie D, Wathen NC, MacDonald TT. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997;158:1582-90.
94. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994;54:4726-8.
95. Aparicio T, Kermorgant S, Dessiner V, Lewin MJM, Lehy T. Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats. Carcinogenesis 1999 (in press).
96. Zervos EE, Norman JG, Gower WR, Franz MG, Rosemurgy AS. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J Surg Res 1997;69:367-71.
97. Bu W, Tang ZY, Sun FX, Ye SL, Liu KD, Xue Q, et al. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20. Hepatogastroenterology 1998;45:1056-61.
98. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995;87:293-8.
99. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor Batimastat (BB-94). Cancer Res 1996;56:2815-22.
100. Giavazzi R, Garofalo A, Ferri C, Lucchini V, Bone EA, Chiari S, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 1998;4:985-92.
101. An ZL, Wang XE, Willmott N, Chander SK, Tickle S, Docherty AJP, et al. Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metast 1997;15:184-95.
102. Anderson IC, Shipp MA, Docherty AJP, Teicher BA. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 1996;56:715-8.
103. WojtowiczPraga S, Low J, Marshall J, Ness E, Dickson R, Barter J, et al. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs 1996;14:193-202.
104. Macaulay VM, O'Byrne KJ, Saunders MP, Salisbury A, Long L, Gleeson F, et al. Phase I study of matrix metalloproteinase (MMP) inhibitor batimastat (BB94) in patients (PTS) with malignant pleural effusions (abstract). Br J Cancer 1995;71 (suppl. 24) : 11.
105. Beattie GJ, Smyth JF. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 1998;4:1899-902.
106. Bramhall SR. The matrix metalloproteinases and their inhibitors in pancreatic cancer. Int J Pancreatol 1997;21:1-12.
107. Talbot DC, Brown PD. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 1996;32A : 2528-33.
108. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markors in advanced cancer : selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 1998;4: 1101-9.
109. Rosemurgy A, Harris J, Langleben A, Casper E, Allen R, Rasmussen H. Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced carcinoma of the pancreas (abstract). Proc Am Soc Clin Oncol 1996;15:207-A470.
110. Malfetano J, Teng N, Moore D, Barter J, Lopez A, Schink J, et al. Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced cancer of the ovary: a dose finding study (abstract). Proc Am Soc Clin Oncol 1996;15:283-A764.
111. Boasberg P, Harbaugh B, Roth B, Eisenberger M, Langleben A, Allen R, et al. Marimastat, a novel matrix metalloproteinase inhibitor in patients with hormone-refractory prostate cancer (abstract). Proc Am Soc Clin Oncol 1996;15:258-A671.
112. Primrose J, Bleiberg H, Daniel F, Johson P, Mansi J, Neoptolemos J, et al. A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor in patients with advanced colorectal cancer (abstract). Ann Oncol 1996;7 (suppl. 5) : 35-A159.